Ophthalmology · Stockton, CA
NPI
1427029768
Since 2006
Specialty
Ophthalmology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1805 N California St, Auite 101
Stockton, CA, 95204
Phone (209) 948-5515
Groups this clinician bills Medicare through
Medicare paid, 2024
$307K
3,916 services
Medicare patients, 2024
1,288
Average age 76
Drug cost, 2024
$326K
1,723 prescriptions
Company payments, 2025
$221
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kala Swamynathan was code 99214 (office e&m - established), 938 times for 885 patients. In total Kala Swamynathan billed 3,916 services in 30 codes, and Medicare paid $307K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-07-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 938 | 885 | $109.96 | $103K |
| 92134 Computerized Ophthalmic Imaging | Office | 765 | 626 | $38.02 | $29K |
| 99213 Office E&M - Established | Office | 585 | 418 | $80.38 | $47K |
| 92250 Angiography | Office | 518 | 461 | $34.44 | $18K |
| 92083 Vision, Hearing, and Speech Services | Office | 333 | 316 | $61.74 | $21K |
| 92014 Ophthalmological E&M | Office | 157 | 157 | $121.53 | $19K |
| 99204 Office E&M - New | Office | 125 | 125 | $130.35 | $16K |
| 92133 Computerized Ophthalmic Imaging | Office | 119 | 112 | $31.53 | $3,752 |
| 92012 Ophthalmological E&M | Office | 86 | 81 | $90.17 | $7,755 |
| 76514 Ultrasound - Nonspecific | Office | 57 | 57 | $9.03 | $514 |
| 92285 Standard X-ray | Office | 41 | 41 | $20.32 | $833 |
| 92020 Ophthalmological E&M | Office | 36 | 35 | $23.52 | $847 |
| 92082 Vision, Hearing, and Speech Services | Office | 32 | 32 | $46.75 | $1,496 |
| 15823 Skin | Facility | 31 | 31 | $794.58 | $25K |
| 66821 Cataract Surgery | Office | 25 | 20 | $312.12 | $7,803 |
By year: 2022 $283K for 3,746 services; 2023 $292K for 3,691 services; 2024 $307K for 3,916 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kala Swamynathan prescribed most often to Medicare patients was Latanoprost, with 471 prescriptions and refills. In total Kala Swamynathan wrote 1,723 Medicare prescriptions that cost $326K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Latanoprost Generic | 471 | 1,151 | 149 | $6,077 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 197 | 433 | 54 | $3,338 |
| Azelastine Hcl Generic | 107 | 164 | 43 | $5,429 |
| Lumigan Bimatoprost | 84 | 205 | 25 | $53K |
| Timolol Maleate Generic | 78 | 208 | 26 | $1,051 |
| Brimonidine Tartrate Generic | 71 | 162 | 25 | $1,064 |
| Rocklatan Netarsudil Mesylat/Latanoprost | 70 | 97 | 18 | $33K |
| Cyclosporine Generic | 61 | 138 | 26 | $32K |
| Dorzolamide Hcl Generic | 59 | 144 | 23 | $1,315 |
| Restasis Cyclosporine | 59 | 127 | 24 | $76K |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 51 | 51 | 41 | $583 |
| Vyzulta Latanoprostene Bunod | 40 | 71 | 12 | $24K |
| Simbrinza Brinzolamide/Brimonidine Tart | 40 | 64 | 12 | $11K |
| Erythromycin Erythromycin Base | 39 | 39 | 34 | $342 |
| Brinzolamide Generic | 30 | 61 | 12 | $4,386 |
Brand drugs: 873 claims; generic drugs: 850 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kala Swamynathan $221 ($221 in general payments such as food, travel and fees) from 6 companies. The largest payer was Bausch & Lomb Americas Inc. with $62.08.
| Company | Payments | Amount |
|---|---|---|
| Bausch & Lomb Americas Inc. BLCO | 3 | $62.08 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 2 | $52.29 |
| Abbvie Inc. ABBV | 2 | $42.78 |
| Dompe US, Inc. | 1 | $24.68 |
| Thea Pharma Inc. | 1 | $24.04 |
| Biotissue Holdings Inc. | 1 | $14.65 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.